GENMAB A/S

Genmab A/S announced a capital increase of 24,592 shares as a result of employee warrant exercises. This action, conducted without preemption rights for existing shareholders, generated approximately DKK 37.9 million in proceeds for the company. The increase represents about 0.04% of the company's share capital, bringing the total nominal value to DKK 62,377,844.

Genmab reported strong financial results for the first half of 2026, with revenue increasing 25% to $2,051 million, primarily due to higher royalties from DARZALEX and Kesimpta, and increased EPKINLY net product sales. The company also updated its full-year 2026 financial guidance upwards for revenue and adjusted operating profit. Additionally, Genmab announced positive Phase 3 clinical trial results for epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival.

Genmab A/S announced that worldwide net trade sales of DARZALEX (daratumumab), including DARZALEX FASPRO, reached $4,207 million in the second quarter of 2026. Sales in the U.S. accounted for $2,435 million, while the rest of the world contributed $1,772 million. Genmab receives royalties on these worldwide net sales from Johnson & Johnson.

Genmab A/S announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, evaluating epcoritamab in combination with lenalidomide for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The trial met its primary objective, showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS). The risk of disease progression and death was reduced by 60% (HR 0.40) in the U.S. and 56% (HR 0.44) outside the U.S. Genmab and AbbVie plan to engage global regulatory authorities based on these results.

Genmab A/S announced a capital increase of 185 shares following the exercise of employee warrants. The new shares were subscribed at DKK 1,334.50 each, generating approximately DKK 0.2 million in proceeds for the company. This increase, representing less than 0.001% of the total share capital, brings the total nominal value of Genmab's share capital to DKK 62,353,252, comprising 62,353,252 shares.

Genmab A/S announced that Orbis Investment Management Limited's stake in the company has decreased, falling below the 5% major shareholder threshold. As of June 12, 2026, Orbis Investment Management Limited controls 3,112,476 shares, representing 4.99% of Genmab's share capital and voting rights, down from a previous holding of 5.0783%. This change was reported under the Danish Capital Markets Act.

Genmab A/S filed a Form 6-K with the U.S. Securities and Exchange Commission on June 15, 2026. This report is incorporated by reference into several of the company's existing Form S-8 registration statements. The filing includes the company's Articles of Association as Exhibit 3.1.

Genmab A/S announced the grant of 15,894 restricted stock units (RSUs) and 15,494 warrants to its employees. Each RSU, awarded cost-free, has a fair value of DKK 1,616.50 and provides a conditional right to one share, vesting after three years. The warrants, also cost-free, have an exercise price of DKK 1,616.50, a fair value of DKK 534.23, vest after three years, and expire on the seventh anniversary of the grant date.

Genmab A/S announced that Michael Kavanagh, a Member of the Board of Directors, sold 526 shares of the company. The transactions took place on May 29, 2026, on NASDAQ Copenhagen, with each share sold at a price of DKK 1,734.75. This disclosure is made in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse.

Genmab A/S filed a Form 6-K with the SEC, which included its Articles of Association as an exhibit. This report is incorporated by reference into several of the company's existing Form S-8 registration statements, representing a routine regulatory update.